China's National Medicinal Products Administration (NMPA) has conditionally approved telitacicept for treating adult patients with IgA nephropathy (IgAN), based on positive Phase 2 and Phase 3 trial results. Telitacicept is the first therapy targeting BAFF/APRIL cytokines approved for IgAN, showing significant reduction in proteinuria and preservation of kidney function. Developed by RemeGen in China and licensed by Vor Bio outside Greater China, this approval marks the fourth indication for telitacicept, which is also being developed globally for other autoimmune diseases. This milestone highlights the potential of dual BAFF/APRIL inhibition to address autoimmune kidney disease and could lead to broader use worldwide.
Leading Japanese companies, startups, and research institutions are developing specialized AI models using NVIDIA Nemotron open models to address Japan's unique language, industrial, and workforce challenges. These AI applications range from enterpri...
ARCpoint Inc. announced it will likely miss the July 29, 2026 deadline to file its annual financial statements and related reports due to a lack of funds to pay auditors. The company has applied for a Management Cease Trade Order (MCTO) and awaits ap...
The Rosen Law Firm is investigating potential securities claims against Putnam Investment Management, LLC, alleging that the company may have provided misleading business information to investors. Investors who purchased Putnam stock-based mutual fun...
Several stocks experienced significant declines today driven by company-specific events. SANUWAVE Health's shares dropped 39.21% despite strong revenue guidance, Twin Vee Powercats fell 30.95% amid a legal investigation, and Gorilla Technology declin...
The phase III ENDURANCE trial showed that two years of lenalidomide maintenance therapy offers the same long-term survival benefit as indefinite treatment for patients with standard-risk multiple myeloma who are not transplant candidates. After nearl...
